AR074196A1 - Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas - Google Patents
Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicasInfo
- Publication number
- AR074196A1 AR074196A1 ARP090104435A ARP090104435A AR074196A1 AR 074196 A1 AR074196 A1 AR 074196A1 AR P090104435 A ARP090104435 A AR P090104435A AR P090104435 A ARP090104435 A AR P090104435A AR 074196 A1 AR074196 A1 AR 074196A1
- Authority
- AR
- Argentina
- Prior art keywords
- physiological conditions
- under physiological
- reduce
- large macromolecule
- formulation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 230000004962 physiological condition Effects 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920002521 macromolecule Polymers 0.000 abstract 4
- 230000002776 aggregation Effects 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 2
- 238000007920 subcutaneous administration Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 238000005189 flocculation Methods 0.000 abstract 1
- 230000016615 flocculation Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Abstract
Método para reducir la agregacion e inhibir la floculacion de una macromolécula grande, tal como una proteína, bajo condiciones fisiologicas, mediante la adicion de 5% a 20% de polivinilpirrolidona (PVP) con un rango de peso molecular de 2000 a 54.000 daltons. Método para reducir al mínimo la inflamacion en el sitio de inyeccion durante la administracion subcutánea de una macromolécula grande. Formulaciones farmacéuticas para la administracion subcutánea de una macromolécula grande, y métodos para tratar un cáncer CD20 positivo o una enfermedad autoinmune, que comprende administrar un anticuerpo anti-CD20 humanizado en una formulacion farmacéutica de la solicitud. Método de diálisis in vitro para evaluar la capacidad de un excipiente de reducir la agregacion de un anticuerpo u otra macromolécula grande bajo condiciones fisiologicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11543908P | 2008-11-17 | 2008-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074196A1 true AR074196A1 (es) | 2010-12-29 |
Family
ID=42170394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104435A AR074196A1 (es) | 2008-11-17 | 2009-11-16 | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20110300135A1 (es) |
| EP (1) | EP2358394A4 (es) |
| JP (2) | JP2012509270A (es) |
| KR (2) | KR20110097772A (es) |
| CN (2) | CN102281902B (es) |
| AR (1) | AR074196A1 (es) |
| AU (1) | AU2009313756B2 (es) |
| BR (1) | BRPI0916042A2 (es) |
| CA (1) | CA2742990A1 (es) |
| CL (1) | CL2011001131A1 (es) |
| IL (1) | IL212532A0 (es) |
| MX (1) | MX2011005056A (es) |
| PE (2) | PE20142332A1 (es) |
| RU (1) | RU2011124527A (es) |
| TW (1) | TW201021831A (es) |
| WO (1) | WO2010057109A1 (es) |
| ZA (1) | ZA201102998B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101364902B1 (ko) | 2003-11-05 | 2014-02-21 | 로슈 글리카트 아게 | 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체 |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| HUE029849T2 (en) | 2014-05-23 | 2017-04-28 | Ares Trading Sa | Liquid pharmaceutical composition |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| CA2950577A1 (en) * | 2014-05-27 | 2015-12-03 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
| EP3053572A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
| HK1250997A1 (zh) * | 2015-05-01 | 2019-01-18 | 基因泰克公司 | 掩蔽抗cd3抗体和使用方法 |
| KR20190074300A (ko) | 2016-11-15 | 2019-06-27 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약 |
| JP7341061B2 (ja) | 2016-11-22 | 2023-09-08 | エレクトロファイ， インコーポレイテッド | 治療用又は診断用薬剤を含む粒子並びにその懸濁液及び使用方法 |
| MX2019013072A (es) | 2017-05-02 | 2019-12-16 | Merck Sharp & Dohme | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11077059B2 (en) | 2017-07-25 | 2021-08-03 | Elektrofi, Inc. | Electrospraying formation of particles including agents |
| US12115262B2 (en) | 2018-05-24 | 2024-10-15 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| AU2019377456A1 (en) | 2018-11-07 | 2021-05-27 | Merck Sharp & Dohme Llc | Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| WO2020160323A2 (en) | 2019-01-31 | 2020-08-06 | Elektrofi, Inc. | Particle formation and morphology |
| PH12021551916A1 (en) | 2019-02-18 | 2022-05-23 | Lilly Co Eli | Therapeutic antibody formulation. |
| WO2020264313A1 (en) * | 2019-06-28 | 2020-12-30 | Zymo Research Corporation | Compositions for the stabilization of cell-free nucleic acids and methods thereof |
| JP7781743B2 (ja) * | 2019-09-13 | 2025-12-08 | エレクトロフィ，インコーポレイテッド | 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法 |
| WO2021212019A1 (en) | 2020-04-17 | 2021-10-21 | Elektrofi, Inc. | Methods of forming particles by continuous droplet formation and dehydration |
| CN116370408B (zh) * | 2020-06-17 | 2025-12-02 | 成都瑞沐生物医药科技有限公司 | 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂 |
| US12351643B2 (en) | 2020-11-04 | 2025-07-08 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
| US12492261B2 (en) | 2020-11-04 | 2025-12-09 | Genentech, Inc. | Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodies |
| TWI838660B (zh) | 2020-11-04 | 2024-04-11 | 美商建南德克公司 | 以抗cd20/抗cd3雙特異性抗體和抗cd79b抗體藥物結合物治療的給藥方法 |
| EP4337330A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| TW202337494A (zh) | 2021-11-16 | 2023-10-01 | 美商建南德克公司 | 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物 |
| US11958906B2 (en) | 2022-04-13 | 2024-04-16 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1234383A (en) * | 1982-03-17 | 1983-09-22 | Inter-Yeda Ltd. | Interferon stabilised with polyvinyl-pyrrolidone |
| US5961955A (en) * | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| EP1572744B1 (en) * | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| UA99933C2 (ru) * | 2003-04-09 | 2012-10-25 | Дженентек, Инк. | Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
| CA2577133A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2006083761A2 (en) * | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| EP2164871A2 (en) * | 2007-06-12 | 2010-03-24 | Wyeth a Corporation of the State of Delaware | Anti-cd20 therapeutic compositions and methods |
-
2009
- 2009-11-16 TW TW098138928A patent/TW201021831A/zh unknown
- 2009-11-16 PE PE2014001174A patent/PE20142332A1/es not_active Application Discontinuation
- 2009-11-16 AU AU2009313756A patent/AU2009313756B2/en not_active Expired - Fee Related
- 2009-11-16 CN CN2009801546655A patent/CN102281902B/zh not_active Expired - Fee Related
- 2009-11-16 WO PCT/US2009/064613 patent/WO2010057109A1/en not_active Ceased
- 2009-11-16 EP EP09826921A patent/EP2358394A4/en not_active Withdrawn
- 2009-11-16 JP JP2011536561A patent/JP2012509270A/ja not_active Ceased
- 2009-11-16 PE PE2011001039A patent/PE20120204A1/es not_active Application Discontinuation
- 2009-11-16 KR KR1020117011109A patent/KR20110097772A/ko not_active Ceased
- 2009-11-16 KR KR1020147027470A patent/KR20140133588A/ko not_active Ceased
- 2009-11-16 CA CA2742990A patent/CA2742990A1/en not_active Abandoned
- 2009-11-16 AR ARP090104435A patent/AR074196A1/es unknown
- 2009-11-16 RU RU2011124527/10A patent/RU2011124527A/ru not_active Application Discontinuation
- 2009-11-16 BR BRPI0916042A patent/BRPI0916042A2/pt not_active IP Right Cessation
- 2009-11-16 MX MX2011005056A patent/MX2011005056A/es active IP Right Grant
- 2009-11-16 CN CN201310481798.1A patent/CN103705930A/zh active Pending
-
2011
- 2011-04-20 ZA ZA2011/02998A patent/ZA201102998B/en unknown
- 2011-04-28 IL IL212532A patent/IL212532A0/en unknown
- 2011-05-13 US US13/107,082 patent/US20110300135A1/en not_active Abandoned
- 2011-05-16 CL CL2011001131A patent/CL2011001131A1/es unknown
-
2013
- 2013-11-26 US US14/090,259 patent/US20140308270A1/en not_active Abandoned
-
2015
- 2015-03-24 JP JP2015061508A patent/JP2015157820A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201102998B (en) | 2013-06-26 |
| BRPI0916042A2 (pt) | 2015-11-10 |
| JP2015157820A (ja) | 2015-09-03 |
| IL212532A0 (en) | 2011-06-30 |
| EP2358394A4 (en) | 2013-03-06 |
| JP2012509270A (ja) | 2012-04-19 |
| US20110300135A1 (en) | 2011-12-08 |
| CN102281902A (zh) | 2011-12-14 |
| CA2742990A1 (en) | 2010-05-20 |
| PE20120204A1 (es) | 2012-03-03 |
| CN102281902B (zh) | 2013-11-13 |
| AU2009313756A1 (en) | 2010-05-20 |
| AU2009313756B2 (en) | 2015-02-26 |
| MX2011005056A (es) | 2011-05-31 |
| TW201021831A (en) | 2010-06-16 |
| CN103705930A (zh) | 2014-04-09 |
| HK1164750A1 (en) | 2012-09-28 |
| RU2011124527A (ru) | 2012-12-27 |
| KR20140133588A (ko) | 2014-11-19 |
| WO2010057109A1 (en) | 2010-05-20 |
| KR20110097772A (ko) | 2011-08-31 |
| EP2358394A1 (en) | 2011-08-24 |
| CL2011001131A1 (es) | 2012-02-03 |
| US20140308270A1 (en) | 2014-10-16 |
| PE20142332A1 (es) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074196A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| CY1123597T1 (el) | Σκευασματα ινσουλινης για γρηγορη προσληψη | |
| EP2358395A4 (en) | METHOD AND FORMULATION FOR REDUCING THE AGGREGATION OF A MACROMOLECULUM UNDER PHYSIOLOGICAL CONDITIONS | |
| CY1118373T1 (el) | Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος | |
| AR068816A1 (es) | Composiciones de brimonidina mejorada para el tratamiento del eritema | |
| IN2012DN00407A (es) | ||
| EA201170940A1 (ru) | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела | |
| SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| EA201290171A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| MX358491B (es) | Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa. | |
| GB0814302D0 (en) | Compounds and methods | |
| BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
| NZ595767A (en) | Composition for the treatment of prostate cancer | |
| CO7151496A2 (es) | Agentes terapeúticos para administración subcutánea optimizados | |
| RU2013123646A (ru) | Комбинированная композиция | |
| MY180502A (en) | Compound of glycosaminoglycan, preparation method and use thereof | |
| RU2013110003A (ru) | Комбинация соединений для лечения или предотвращения кожных заболеваний | |
| EA201200185A1 (ru) | Фармацевтическая композиция для пероральной доставки дииндолилметана | |
| AR078170A1 (es) | Metodos para el tratamiento de tumores cerebrales | |
| AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| AU2012253610A8 (en) | Compositions and methods for treating cancer | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. | |
| EP2525819A4 (en) | IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |